GSK Predicts Significant Restless Legs Market For Requip
The supplemental NDA for the Parkinson's therapy marks the first drug approval for restless legs syndrome. GSK says one in 10 adults have the condition.
The supplemental NDA for the Parkinson's therapy marks the first drug approval for restless legs syndrome. GSK says one in 10 adults have the condition.